The FDA’s refusal to review Moderna’s mRNA-based flu vaccine is “part of a disturbing pattern” of moving regulatory goalposts, according to Clay Alspach, executive director of the Alliance for mRNA Medicines.

The whiplash over a new potential flu vaccine from Moderna, which went from rejected to approved for review in a matter of days, has illustrated a new reality plaguing the Cambridge biotech company and other vaccine makers: Political headwinds are now an unavoidable and unpredictable factor in their business model.

Moderna is suing Pfizer and BioNTech for infringing patents central to Moderna's mRNA technology platform used to develop the COVID vaccine, the company said in a press release Friday. A widely distributed COVID vaccine developed by Pfizer and BioNTech ...

Booster vaccines reduced the risk of COVID‑19-related hospitalization and death, according to a new study of over 3 million adults who had the autumn 2022 vaccine in England. The research, led by the universities of Bristol and Oxford,

Stocks of COVID-19 vaccine makers take a dive following Washington Post report, while Moderna stresses multiple agencies have backed their safety Stocks of COVID vaccine makers dropped after the Washington Post reported that Trump administration health ...

Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump administration health officials intend to link the vaccines to 25 ...